一分钟看懂
这是一项关于多发性骨髓瘤的I 期研究，登记的药物或干预包括ABBV-438，当前状态为招募中。登记地点显示中国天津、杭州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ABBV-438 · I 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出2项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Institute of Hematology and Blood Diseases Hospital /ID# 279208 · 天津
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 279207 · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Has relapsed or refractory Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the standard International Myeloma Working Group (IMWG) (2016) response criteria:
- Relapsed defined as previously treated myeloma that progresses and requires initiation of salvage therapy;
- Refractory defined as disease that is nonresponsive (failure to achieve minimal response) while on last therapy, or progresses within 60 days of last therapy.
- * Has measurable disease at screening, defined by at least 1 of the following within 28 days prior to enrollment:
- Serum M-protein \>= 0.5 g/dL (\>=5 g/L); OR;
- Urine M-protein \>= 200 mg/24 hours; OR;
- Involved serum free light chain (sFLC) \>= 10 mg/dL (100mg/L), provided serum FLC ratio is abnormal;
- Must have had 3 or more prior lines of therapy with exposure to a proteasome inhibitor (PI), an immunomodulatory imide drugs (IMiD), and an anti-CD38 therapy and are intolerant to, or unable to access, available therapies that are known to confer clinical benefit to participants with relapsed or refractory (R/R) MM. Note: A line of therapy consists of relapsed or refractory 1 complete cycle of a single agent, a regimen consisting of a combination of several drugs, or a planned sequential therapy of various regimens.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07409246；登记信息更新于 2026-09-29；本站同步于 2026-10-08，中国中心当前名额未经人工确认。